PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
3.31%
Revenue growth exceeding 1.5x Medical - Pharmaceuticals median of 1.10%. Joel Greenblatt would investigate if growth quality matches quantity.
3.41%
Cost growth exceeding 1.5x Medical - Pharmaceuticals median of 1.13%. Jim Chanos would check for structural cost disadvantages.
2.91%
Gross profit growth exceeding 1.5x Medical - Pharmaceuticals median of 1.38%. Joel Greenblatt would investigate competitive advantages.
-0.39%
Margin decline while Medical - Pharmaceuticals median is 0.06%. Seth Klarman would investigate competitive position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.89%
Other expenses reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
1.88%
Operating expenses growth exceeding 1.5x Medical - Pharmaceuticals median of 0.36%. Jim Chanos would check for waste.
3.15%
Total costs growth exceeding 1.5x Medical - Pharmaceuticals median of 0.52%. Jim Chanos would check for waste.
-7.14%
Interest expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
6.12%
D&A growth exceeding 1.5x Medical - Pharmaceuticals median of 1.54%. Jim Chanos would check for overinvestment.
5.05%
EBITDA growth exceeding 1.5x Medical - Pharmaceuticals median of 1.23%. Joel Greenblatt would investigate advantages.
1.68%
Margin change of 1.68% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
7.71%
Operating income growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
4.25%
Margin change of 4.25% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
-15.70%
Other expenses reduction while Medical - Pharmaceuticals median is -6.54%. Seth Klarman would investigate advantages.
4.55%
Pre-tax income growth exceeding 1.5x Medical - Pharmaceuticals median of 1.21%. Joel Greenblatt would investigate advantages.
1.20%
Pre-tax margin growth exceeding 1.5x Medical - Pharmaceuticals median of 0.60%. Joel Greenblatt would investigate advantages.
5.41%
Tax expense change of 5.41% versus flat Medical - Pharmaceuticals. Walter Schloss would verify strategy.
4.16%
Net income growth exceeding 1.5x Medical - Pharmaceuticals median of 2.75%. Joel Greenblatt would investigate advantages.
0.82%
Net margin growth below 50% of Medical - Pharmaceuticals median of 1.95%. Jim Chanos would check for deterioration.
4.15%
EPS growth 1.25-1.5x Medical - Pharmaceuticals median of 3.76%. Mohnish Pabrai would examine sustainability.
4.15%
Diluted EPS growth near Medical - Pharmaceuticals median of 3.79%. Charlie Munger would verify industry dynamics.
-0.00%
Share count reduction while Medical - Pharmaceuticals median is 0.24%. Seth Klarman would investigate strategy.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.17%. Seth Klarman would investigate strategy.